LILRB1 and triple-negative breast carcinoma: CD85j engagement on NK cells limits their effector functions (26, 50) and its up-regulation in PBNK from triple negative breast cancer patients has been associated with impaired antibody-dependent cell-mediated cytotoxicity (ADCC) elicited by Cetuximab (51).